Current Opinion in Biomedical Engineering is a renowned journal published by Elsevier, focusing on the cutting-edge developments and critical assessments in the fields of biomedical engineering and related disciplines. With an ISSN of 2468-4511, it provides a valuable platform for researchers and professionals to disseminate their insights and discoveries in areas such as bioengineering, biomaterials, and medicine. Its impressive impact factor positions it in the Q2 category for several fields, including Bioengineering and Biomedical Engineering, highlighting its influence and relevance in ongoing scientific dialogues. The journal’s unique format of opinion pieces and reviews encourages innovative thinking and fosters collaboration among experts. As an essential resource for those engaged in the life sciences and engineering, Current Opinion in Biomedical Engineering serves to stimulate discussion, promote knowledge exchange, and drive advancements in biomedical applications. Set in the Netherlands at Radarweg 29, 1043 NX Amsterdam, the journal is accessible through various academic platforms, enabling a global readership to engage with the latest scholarly work in this dynamic field.

Journal of Tissue Engineering and Regenerative Medicine, published by WILEY, stands as a pivotal platform in the fields of biomaterials, biomedical engineering, and regenerative medicine. With an ISSN of 1932-6254 and an E-ISSN of 1932-7005, this journal, based in the United Kingdom, has consistently delivered high-quality research since its inception in 2006, converging critical insights through 2024. With an impressive citation profile reflected in its Scopus rankings—specifically a rank of #58 in Medicine and #75 in Biomedical Engineering—the journal is acknowledged for its substantial impact, as demonstrated by its competitive quartile standings in 2023. Notably, it maintains a Q3 ranking in Biomaterials and Q2 in both Biomedical Engineering and Medicine (miscellaneous), showcasing its influence and relevance in the rapidly evolving interplay between engineering and medicine. The journal serves as a vital resource for researchers and practitioners aiming to stay abreast of innovations and breakthroughs in regenerative therapies, tissue scaffolds, and biomaterials. While not an open-access publication, it fosters academic dialogue and knowledge dissemination that is crucial for advancing the field.

Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

Tissue Engineering Part C: Methods is a prestigious academic journal published by MARY ANN LIEBERT, INC, specializing in the dynamic and rapidly evolving fields of bioengineering and biomedical engineering. With an ISSN of 1937-3384 and E-ISSN 1937-3392, this journal provides a platform for the dissemination of cutting-edge research from 2008 to 2024, showcasing methodologies that advance the science of tissue engineering. Ranked in the second and third quartiles across several categories in 2023, including a notable Q2 in Biomedical Engineering, the journal is recognized for its contributions to the interface of biology and engineering. Additionally, it holds commendable Scopus ranks that highlight its influence and reach within the scientific community. Although it does not offer open access, the journal remains vital for researchers, professionals, and students seeking insightful articles that bridge the gap between theoretical research and practical application in tissues and regenerative medicine. With its rigorous peer-review process and commitment to quality, Tissue Engineering Part C: Methods continues to be an essential resource for those at the forefront of tissue engineering innovations.

APL Bioengineering is a premier open-access journal published by AIP Publishing, dedicated to advancing the field of bioengineering and its interdisciplinary applications. Established in 2017, this journal serves as a vital platform for researchers, professionals, and students interested in the critical intersections of bioengineering, biomaterials, biomedical engineering, and biophysics. With an impressive impact factor and consistent rankings in the Q1 category across multiple domains, including biochemistry and materials science, APL Bioengineering has positioned itself among the top journals in its field. The journal aims to publish innovative original research, comprehensive reviews, and insightful case studies that further the understanding and application of bioengineering principles. Since its inception, APL Bioengineering has fostered a community of thought leaders, providing open access to ensure broad dissemination of knowledge and advancements that underpin the future of biomedical innovation.

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.

Frontiers in Bioengineering and Biotechnology, published by FRONTIERS MEDIA SA in Switzerland, stands as a leading platform for innovative research and developments in the fields of bioengineering and biotechnology. Since its inception in 2013, this Open Access journal has garnered significant recognition, reflected in its impressive category rankings: Q1 in Biomedical Engineering and Q2 in Bioengineering, Biotechnology, and Histology for 2023. With a focus on fostering collaboration and knowledge sharing, it aims to provide researchers, professionals, and students with access to pioneering studies that push the boundaries of science and technology. The journal, which is indexed in prominent databases, boasts high visibility and impact, evidenced by its impressive rankings across various categories in Scopus. As it continues to converge from 2013 to 2024, Frontiers in Bioengineering and Biotechnology is dedicated to shaping the discourse in its field and promoting advancements that have the potential to transform healthcare and environmental sustainability.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.

Regenerative Medicine, published by Taylor & Francis Ltd, is a pivotal journal within the field of biomedical research, focusing on the innovative advances in regenerative and restored functions in human health. With an ISSN of 1746-0751 and an E-ISSN of 1746-076X, this esteemed journal boasts a commendable impact factor within its categories, notably holding the Q2 status in Embryology and Q3 in Biomedical Engineering as of 2023. Covering a broad spectrum of topics from stem cell research to tissue engineering, it serves as a crucial platform for interdisciplinary collaboration among researchers, professionals, and students dedicated to the regeneration of tissues and organs. Given its comprehensive scope from 2006 to 2024, the journal continues to attract high-quality manuscripts that advance the frontiers of knowledge in regenerative medicine. Researchers and practitioners alike are encouraged to engage with the latest findings and methodologies disseminated in this vital publication.

Biomedical Materials, published by IOP Publishing Ltd, is a premier journal dedicated to the rapidly evolving field of biomedical engineering and materials science. With a robust impact factor showcasing its influence, this journal serves as a vital platform for disseminating pioneering research from 2006 to 2024. Covering an array of interdisciplinary topics—ranging from biomaterials to bioengineering and applied chemistry—the journal consistently ranks in the second quartile across multiple categories including Bioengineering (Q2), Biomaterials (Q2), and Biomedical Engineering (Q2) as of 2023. Researchers, professionals, and students alike benefit from its contributions, exploring innovative solutions at the intersection of biology and material science. Although not an Open Access journal, Biomedical Materials remains essential in advancing our understanding and facilitating discussions surrounding state-of-the-art materials that revolutionize medical applications and enhance patient care.